Lantheus Holdings, Inc. (LNTH) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Lantheus Holdings, Inc. (LNTH) closed at USD 100.00 on 2026-10-14, a change of +74.4 % over the past year, with a market capitalization of USD 6.53B.

Lantheus Holdings, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Lantheus Holdings, Inc. key figures

Previous close

USD 100.00 (2026-10-14)

1-year change

+74.4 %

Market cap

USD 6.53B

Enterprise value

USD 6.56B

P/E ratio (trailing)

24.21

P/E ratio (forward)

15.68

EPS (trailing)

4.13

EPS (forward)

6.38

PEG ratio

n/a

Price to book

4.97

Revenue growth

2.7 %

Earnings growth

-0.9 %

Dividend per share (trailing)

0.00

Short ratio

3.67

Employees

1,193

Analyst consensus (third-party)

hold

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Lantheus Holdings, Inc. and compare it with other stocks.